These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Effects of ecstasy on the body]. Saarijärvi S; Lopperi M Duodecim; 2003; 119(13):1211-5. PubMed ID: 12908183 [No Abstract] [Full Text] [Related]
23. More about parkinsonism after taking ecstasy. Borg GJ N Engl J Med; 1999 Oct; 341(18):1400; author reply 1401. PubMed ID: 10577095 [No Abstract] [Full Text] [Related]
24. What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease? Kish SJ Mov Disord; 2003 Nov; 18(11):1219-23. PubMed ID: 14639660 [No Abstract] [Full Text] [Related]
25. An in vitro approach to assessing a potential drug interaction between MDMA (ecstasy) and caffeine. Downey C; Daly F; O'Boyle KM Toxicol In Vitro; 2014 Mar; 28(2):231-9. PubMed ID: 24211539 [TBL] [Abstract][Full Text] [Related]
26. MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the contemporary human and animal research perspective. Parrott AC; Marsden CA J Psychopharmacol; 2006 Mar; 20(2):143-6. PubMed ID: 16510473 [No Abstract] [Full Text] [Related]
27. [Comment on R. Thomasius, M. Schmolke, D. Kraus: MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae]. Gouzoulis-Mayfrank E; Hermle L; Kovar KA; Sass H Fortschr Neurol Psychiatr; 1999 Dec; 67(12):574-6. PubMed ID: 10683753 [No Abstract] [Full Text] [Related]
28. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479 [TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography findings in heavy users of MDMA. Holland J Lancet; 1999 Feb; 353(9152):592-3. PubMed ID: 10029009 [No Abstract] [Full Text] [Related]
31. MDMA: fact and fallacy, and the need to increase knowledge in both the scientific and popular press. Green AR Psychopharmacology (Berl); 2004 May; 173(3-4):231-3. PubMed ID: 14985917 [No Abstract] [Full Text] [Related]
32. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity. Biezonski DK; Meyer JS J Neurochem; 2010 Feb; 112(4):951-62. PubMed ID: 20002520 [TBL] [Abstract][Full Text] [Related]
33. Malignant hyperpyrexia in an MDMA ("Ecstasy") abuser. McCoy EP; Renfrew C; Johnston JR; Lavery G Ulster Med J; 1994 Apr; 63(1):103-7. PubMed ID: 8658983 [No Abstract] [Full Text] [Related]
34. Ecstasy: are animal data consistent between species and can they translate to humans? Easton N; Marsden CA J Psychopharmacol; 2006 Mar; 20(2):194-210. PubMed ID: 16510478 [TBL] [Abstract][Full Text] [Related]
35. MDMA ("ecstasy") abuse as an example of dopamine neuroplasticity. Schenk S Neurosci Biobehav Rev; 2011 Apr; 35(5):1203-18. PubMed ID: 21184779 [TBL] [Abstract][Full Text] [Related]